UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.001 per share PETS NASDAQ Global Select Market FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ ...

PetMed Express, Inc. (NASDAQ:PETS) Q1 2025 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Reed Anderson - Investor Relations, ICR Sandra Campos - Chief Executive Officer & President Christine Chambers - Chief Financial Officer Conference Call Participants Ryan Meyers - Lake Street Capital Markets Operator Greetings and welcome to PetMed Express First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session wil ...

Exhibit 99.1 PetMeds® Announces Fiscal 2025 First Quarter Financial Results Net Income for first quarter fiscal 2025 was $3.8 million or $0.18 diluted earnings per share Delray Beach, Florida, August 6, 2024, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2024. Quarterly Highlights for Q1, Fiscal 2025 • Net sales were $68 million, (13)% lower than the prior year comparable quarter. • Net income was $3 ...

DELRAY BEACH, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (NASDAQ:PETS) will hold a conference call on Tuesday, August 6, 2024 at 4:30pm Eastern time to discuss its financial results for the fiscal first quarter ended June 30, 2024. Financial results will be issued in a press release prior to the call. Date: Tuesday, August 6, 2024 Time: 4:30pm Eastern time (1:30pm Pacific time) U.S. dial-in number: 844-826-3035 International number: 412-317-519 ...

Investors can contact the law firm at no cost to learn more about recovering their losses Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. On this news, PetMed's stock price fell $0.54 per share, or 11.46%, to close ...

The investigation concerns whether PetMed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On June 11, 2024, PetMed issued a press release announcing its financial results for its fourth quarter and fiscal year 2024. Among other items, PetMed reported a net loss per share of $0.25, compared to a net loss per share of $0.01 in the year-ago period. Although PetMed reported a net increase in sales year over year, that was outweighed by an incre ...

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (561) 526-4444 Securities registered pursuant to ...

Financial Data and Key Metrics Changes - The fourth quarter fiscal year 2024 sales were $66.5 million, a 6.6% increase from $62.4 million in the same period last year [12] - Gross profit margin decreased to 27.3% from 27.9% year-over-year, attributed to increased G&A and advertising expenses [13][14] - Net loss for the fourth quarter was $5 million or $0.25 per diluted share, compared to a net loss of $200,000 or $0.01 per diluted share in the same period last year [70] Business Line Data and Key Metrics Changes - Consolidated reorder sales increased to $58.9 million, a 4.6% rise compared to $56.2 million in the same period last year [69] - Recurring revenue, including AutoShip & Save sales and PetCareRx membership sales, accounted for 54% of total sales in Q4 fiscal year 2024, up from 52% in Q3 fiscal year 2024 and 44% in the same quarter last year [69] Market Data and Key Metrics Changes - The U.S. pet spending market grew by 7% to $147 billion in 2023, with veterinary care and prescription medications representing about 26% of total spend [32] - The company welcomed approximately 73,000 new pet parents in the quarter, which was relatively flat compared to the same period last year [90] Company Strategy and Development Direction - The company aims to consolidate its brands into a single entity to streamline operations and enhance customer experience [34] - Focus on cash flow generation while enhancing key partnerships, with a healthy liquidity position entering fiscal 2025 [35] - Investment in technology, AI, and automation across departments to improve operational efficiency [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that strategic initiatives will drive growth and improve profitability outcomes [11] - The CEO emphasized the importance of transparency and the need for technology improvements as a focus area [8] - The company is committed to enhancing customer experiences through advanced technology solutions and personalized marketing initiatives [9] Other Important Information - The company has a balance sheet with over $55 million in cash and no debt as of March 31, 2024, allowing for a balanced approach to capital allocation [88] - The newly formed Veterinary Advisory Board will play a crucial role in improving patient care and supporting educational content development [4][10] Q&A Session Summary Question: Has there been stabilization in the core business? - Management noted that they are focused on profitability and creating synergies through the consolidation of businesses to reduce redundancies [23] Question: What metrics can be shared regarding organic growth? - New customer growth was reported as relatively flat for the quarter, with a focus on customer acquisition and retention metrics [24] Question: How will the company manage its cost structure going forward? - Management indicated that they are looking to reduce operating expenses and improve efficiencies across all departments [97]

DELRAY BEACH, Fla., June 11, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its fourth quarter and fiscal year ended March 31, 2024. Net sales for the quarter ended March 31, 2024, were $66.5 million, compared to $62.4 million for the fourth quarter in the prior year, an increase of 6.6%, driven by the acquisition of PetCareRx partially offset by a decline in PetMeds legacy sales. Net loss for the quarter end ...

Quarterly Highlights Net sales for the quarter ended March 31, 2024, were $66.5 million, compared to $62.4 million for the fourth quarter in the prior year, an increase of 6.6%, driven by the acquisition of PetCareRx partially offset by a decline in PetMeds legacy sales. Net loss for the quarter ended March 31, 2024 was $(5.0) million, or $(0.25) diluted earnings per share. This compares to net loss of $(0.2) million, or $(0.01) diluted earnings per share, for the prior year quarter ended March 31, 2023. Th ...